Fireside Chat with Theranos Whistleblowers
By AACC Posted on 12 Jul 2022 |
Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Tuesday, July 26
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center
Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.
After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.
Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.
Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center
Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.
After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.
Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.
Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.
Latest AACC 2022 News
- AACC 2022 Review: International Meetings Rebound After Suffering Long COVID Hiatus
- Faster Method Diagnoses Pediatric Urinary Tract Infections
- Tianlong Showcases Integrated PCR Lab Solutions at AACC 2022
- Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022
- Advanced Instruments Introduces New Automated Osmometer at AACC 2022
- Innovative Smartphone and AI-Based Tests Featured at AACC 2022
- New Tests Presented at AACC 2022 to Solve Challenges in Children's Healthcare
- 10-Minute Sepsis Risk Stratification Test Introduced at AACC 2022
- New System Combining DNA/RNA Extraction and Smart PCR Setup Launched at AACC 2022
- Novel Small Volume Blood Collection Device Launched at AACC 2022
- AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs
- Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022
- Nikon Instruments Displays Latest Clinical Pathology Products at AACC 2022
- Seegene Showcases Latest Molecular Testing Solutions at AACC 2022
- Werfen Introduces New Acute Care Diagnostic Products for CVOR at AACC 2022
- PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology